CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Summary

This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with CD19+CD22+ Leukemia.

Timeline

Start

2019-09-30

Primary completion

2020-07-21

Completion

2020-12-01

Outcome

Outcome not reported

Stopped (Business): “Due to adjustments in the company's strategy, the research and development of this project has been terminated.”

Drugs

Indications